The Salk Polio Vaccine Is Declared Safe and Effective · Chronopin

The Salk Polio Vaccine Is Declared Safe and Effective · Chronopin

Health09/20/2026@HealthDesk
PCV21 Vaccine's Phase 3 Trial in Pneumococcal Immunization Reads Out
Sanofi…Paris, Grand Paris, France
Starts 06/07/2027ESTIMATED 50% CONFIDENCEin 257 daysClinicalTrials.gov^[1] lists 2027-06-07 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of PCV21 Vaccine in pneumococcal immunization reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,195 participants. This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately
0.65
Health09/20/2026@HealthDesk
MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out
GSK…79 New Oxford Street, London, Greater London, United Kingdom
Starts 06/09/2028ESTIMATED 50% CONFIDENCEin 1.7 yearsClinicalTrials.gov^[1] lists 2028-06-09 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.
0.64
Health09/20/2026@HealthDesk
MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
Sanofi…Paris, Grand Paris, France
Starts 03/13/2028ESTIMATED 50% CONFIDENCEin 1.5 yearsClinicalTrials.gov^[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m
0.63
Health09/20/2026@HealthDesk
PG4's Phase 3 Trial in Pneumococcal Disease Reads Out
Pfizer…New York City, New York, United States
Starts 12/30/2028ESTIMATED 50% CONFIDENCEin 2.3 yearsClinicalTrials.gov^[1] lists 2028-12-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups. This study is seeking participants who are: \- infants
0.63
Health09/20/2026@HealthDesk
MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out
Merck & Co.…Rahway, United States
Starts 10/18/2027ESTIMATED 50% CONFIDENCEin 1.1 yearsClinicalTrials.gov^[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of MK-8527 and if people tolerate it
0.60
Health09/20/2026@HealthDesk
C.Difficile Vaccine's Phase 3 Trial in Clostridoides Difficile Associated Disease Reads Out
Pfizer…New York City, New York, United States
Starts 12/11/2028ESTIMATED 50% CONFIDENCEin 2.2 yearsClinicalTrials.gov^[1] lists 2028-12-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for
0.59
Health09/23/2026@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Starts 08/25/2026CONFIRMED 87% CONFIDENCE29 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.58
Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/26/2026CONFIRMED 87% CONFIDENCE120 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.58
Health09/20/2026@HealthDesk
Cagrisema's Phase 3 Trial in Obesity Reads Out
Novo Nordisk…Bagsværd, Gladsaxe Municipality, Denmark
Starts 02/23/2028ESTIMATED 50% CONFIDENCEin 1.4 yearsClinicalTrials.gov^[1] lists 2028-02-23 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Novo Nordisk's phase 3 trial of Cagrisema in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
0.58
Health09/20/2026@HealthDesk
BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
AstraZeneca…Cambridge, United Kingdom
Starts 12/03/2027ESTIMATED 50% CONFIDENCEin 1.2 yearsClinicalTrials.gov^[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
0.57
Health09/21/2026@HealthDesk
Smallpox Is Declared Eradicated
World Health Organization, Avenue Appia 20, 1211 Geneva, SwitzerlandWorld Health Organization
Starts 05/08/1980CONFIRMED 90% CONFIDENCE46.4 years agoThe Thirty-third World Health Assembly declared the global eradication of smallpox on 8 May 1980, the date of the resolution.^[1]
The World Health Assembly certified that smallpox had been wiped from the earth - the only human disease ever eradicated. The last natural case had been in Somalia in 1977, and the campaign that found it had traced and vaccinated outwards from every case for a decade.
0.56
Health09/23/2026@HealthDesk
Abbott Settles Gill Case and 2,000 NEC Formula Claims for $670M
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 08/20/2026CONFIRMED 86% CONFIDENCE34 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 20, 2026" and the 8-K says "On August 20, 2026 ... Abbott entered into agreements to resolve the Gill lawsuit".^[1]
Abbott agreed with three law firms to pay about $670 million to settle the Gill case, a $495 million St. Louis jury award, and NEC claims for about 2,000 other preterm infants fed its specialty formulas. About 1,700 lawsuits covering some 12,700 infants remain.
$670M
0.56